OncoMatch/Clinical Trials/NCT06427239
Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer
Is NCT06427239 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including HRS-4642 and Adebrelimab for pancreatic cancer.
Treatment: HRS-4642 · Adebrelimab — The study is being conducted to evaluate the safety, tolerability and efficacy of HRS-4642 combined with adebelimab in subjects with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment
With failure or absence of standard treatment, and progress within 6 months of adjuvant therapy can also be included in the study
Cannot have received: systemic antitumor therapy
Systemic antitumor therapy was received 4 weeks before the start of the study
Cannot have received: palliative radiotherapy
palliative radiotherapy was completed within 14 days before the first dose
Cannot have received: allogeneic hematopoietic stem cell transplantation
Previously received allogeneic hematopoietic stem cell transplantation
Cannot have received: organ transplantation
Previously received...organ transplantation
Lab requirements
Blood counts
Kidney function
Liver function
Adequate marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify